NeOnc Technologies to Present Brain Cancer Advances to 63 Million TV Viewers on "Health Uncensored with Dr. Drew" Airing Nationwide on Lifetime Network September 25 at 8:00 a.m. ET/PT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Source: Newsfilter
Television Feature: NeOnc Technologies will be featured on Health Uncensored with Dr. Drew Pinsky, airing on September 25th, showcasing their innovative therapies for CNS cancers and a patient's success story with brain cancer remission.
Recent Milestones: The company has secured a $50 million partnership for clinical trials, received FDA authorization for its NEO212 trial, is nearing full enrollment for another trial, and has been awarded $2.5 million in NIH grants, highlighting significant progress in their drug development efforts.
Analyst Views on NTHI
About NTHI
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
